Monocyclic compound having glp-1 receptor agonist activity

A compound represented by formula (I):

• wherein
• A1 is C(R5) or N,
• A2 is C(R6) or N,
• A3 is C(R7) or N,
• R5, R6, and R7 are each independently a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted aromatic heterocyclyl, or substituted or unsubstituted non-aromatic carbocyclyl,
• R2 is substituted or unsubstituted alkyl, or substituted or unsubstituted non-aromatic heterocyclyl,
• -L- is a group represented by:
• wherein
• R1 is a hydrogen atom, or substituted or unsubstituted alkyl,
• R8 is a hydrogen atom, or substituted or unsubstituted alkyl,
• R10s are each independently cyano, halogen, or substituted or unsubstituted alkyl, and
• m is an integer of 1 to 3, and
• R3 is phenyl optionally substituted with substituent group F, 5- or 6-membered aromatic heterocyclyl optionally substituted with substituent group F, bicyclic 9- or 10-membered aromatic heterocyclyl optionally substituted with substituent group F, or 5- to 12-membered non-aromatic heterocyclyl optionally substituted with substituent group F,
• the substituent group F:
• halogen, cyano, alkyl, haloalkyl, alkyloxy, and haloalkyloxy,
• or a pharmaceutically acceptable salt thereof.